Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Board of Regents of The University of Oklahoma is a private company headquartered in Norman, OK, with domestic subsidiaries, specializing in radio broadcasting stations.

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.

Meiji Seika Pharma Co., Ltd. engages in the business of manufacture and distribution of pharmaceutical products. It also engages in the animal health business. The company was founded on October 9, 1916 and is headquartered in Tokyo, Japan.

Active Biotech AB engages in the development of pharmaceutical products. The firm specializes in the medical areas where the immune defense is of significant importance, including neurodegenerative diseases, autoimmune, inflammatory disease, and various forms of cancer. Its portfolio comprises orally active immunomodulatory molecules as well as antibody-based immunotherapy. The company was founded on June 15, 1982 and is headquartered in Lund, Sweden.

Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs. Endogena's approach has the potential of a paradigm shift to treat degenerative conditions related to ageing and genetic disorders. The company implements innovation in the field of regenerative medicine. Their science combines the latest developments in stem cell biology, AI, and expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases.

Yizhou (Shanghai) Biopharmaceutical Co., Ltd., established on 2020-07-29, Business scope includes general items:engaged in biotechnology(remove human stem cells,Development and application of genetic diagnosis and treatment technology),Technology development in the field of medical science and technology,technical consulting,Technical Services,technology transfer,Engineering and Technology Research and Experimental Development;Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),Import and export,Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

The Schepens Eye Research Institute, Inc. operates as an eye research institute. It offers treatment for macular degeneration, diabetic retinopathy, glaucoma, other types of retinal and optic nerve degenerations and damage, dry eye and eye tissue transplants. The company was founded by Charles L. Schepens in 1950 and is headquartered in Boston, MA.

Jinan Bangwen Pharmaceutical Technology Co., Ltd., established on 2015-02-15, Business scope includes medical technology development;Chinese medicine products,Healthy food,Technology development of washing products,Technical Consulting and Technical Services;translation service;office services(Does not include engraved seal);data processing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Zhongshan Ophthalmic Center, part of Sun Yat-Sen University, is a Chinese company located in Guangzhou that operates hospitals.

Nanjing Anji Biotechnology Co., Ltd., established on 2012-04-12, Business scope includes licensed projects:Drug retail;Veterinary drug business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH.

Summit Co., Ltd. is a company headquartered in the South Korea that manufactures electrical measuring, testing and analysis instruments. It was founded in 2007.

Potentia Pharmaceuticals, Inc. operates as a biotechnology company. It focuses on the development of novel therapeutics and drug delivery technologies to address chronic inflammatory diseases. The company was founded by Cedric Francois, David Darst, Alec Machiels and Pascal Deschatelets in 2001 and is headquartered in Crestwood, KY.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

Aqumen Biopharmaceuticals KK is a holding company that provides research and development of therapeutic medicines for macular degeneration. It also develops therapeutics for diabetic retinopathy, diabetic nephropathy, adjuvants for ophthalmic surgery, and intraocular drug delivery systems. The firm's products encompass the ILM-Blue and the MembraneBlue-Dual. The company was founded by Kimihiko Fujisawa and Tadahisa Kagimoto on April 11, 2005 and is headquartered in Fukuoka, Japan.